Literature DB >> 20155609

High dose versus moderate dose methadone maintenance: is there a better outcome?

Ayman Fareed1, Jennifer Casarella, Mary Roberts, Mary Sleboda, Richard Amar, Shreedevi Vayalapalli, Karen Drexler.   

Abstract

Methadone dosing has been an issue of controversy among clinicians for a long time. Few recent studies reported that doses above 100 mg daily seem promising in better control of illicit opiate use for some patients, but more research is needed to support that notion. A retrospective chart review for patients maintained on methadone at Atlanta Veterans Affairs Medical Center was conducted. Patients were categorized into two groups: patients on a methadone dose of 60 to 100 mg daily (n = 34) and patients on a methadone dose greater than 100 mg daily (n = 25). Those charts were compared for urine drug screens for opiates and cocaine (first four from admission and most recent four screens), retention or drop out from the program, and Addiction Severity Index (ASI) composite score at admission and most recent score. The results of the first and last four urine drug screens for opiates showed that the moderate dose group was positive 23% and 17%, respectively. However, the high dose group was positive 14% and 8%, respectively. These results showed statistical significance (Chi-Square = 8.04, df = 3 and p =.03). ASI scores for drugs did not show statistically significant improvement for the moderate dose group (p =.19) but showed statistically significant improvement for the high dose group (p =.0002) when the result of the first and last ASI scores among each group were compared. The ASI scores for family problems showed statistically significant improvement for the moderate dose group (p =.03). High doses of methadone greater than 100 mg daily may provide a better outcome for illicit opiate use among some patients who would not respond to moderate doses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20155609     DOI: 10.1080/10550880903183042

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  14 in total

1.  Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence.

Authors:  Shadi Nahvi; Alain H Litwin; Moonseong Heo; Karina M Berg; Xuan Li; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

2.  Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

Authors:  Leslie Lappalainen; Seonaid Nolan; Sabina Dobrer; Cathy Puscas; Julio Montaner; Keith Ahamad; Huiru Dong; Thomas Kerr; Evan Wood; M-J Milloy
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

3.  The Role of Program Directors in Treatment Practices: The Case of Methadone Dose Patterns in U.S. Outpatient Opioid Agonist Treatment Programs.

Authors:  Jemima A Frimpong; Karen Shiu-Yee; Thomas D'Aunno
Journal:  Health Serv Res       Date:  2016-09-12       Impact factor: 3.402

4.  Rates of mood and anxiety disorders and contributors to continued heroin use in methadone maintenance patients: A comparison by HIV status.

Authors:  Allison J Applebaum; Jacqueline R Bullis; Lara N Traeger; Conall O'cleirigh; Michael W Otto; Mark H Pollack; Steven A Safren
Journal:  Neurobehav HIV Med       Date:  2010-08-10

5.  Posttraumatic stress disorder and one-year outcome in methadone maintenance treatment.

Authors:  Seth Himelhoch; Elyssa Weber; Deborah Medoff; Melanie Charlotte; Sara Clayton; Camille Wilson; Racquel Ware; Jewell Benford
Journal:  Am J Addict       Date:  2012-09-21

6.  Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Authors:  Roger D Weiss; Margaret L Griffin; Jennifer Sharpe Potter; Dorian R Dodd; Jessica A Dreifuss; Hilary S Connery; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2014-04-24       Impact factor: 4.492

7.  A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management.

Authors:  Ashley P Kennedy; Karran A Phillips; David H Epstein; David A Reamer; John Schmittner; Kenzie L Preston
Journal:  Drug Alcohol Depend       Date:  2012-11-26       Impact factor: 4.492

Review 8.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

9.  The nature of methadone diversion in England: a Merseyside case study.

Authors:  Paul Duffy; Helen Baldwin
Journal:  Harm Reduct J       Date:  2012-01-13

10.  Risk factors for fatal outcome in patients with opioid dependence treated with methadone in a family medicine setting in Croatia.

Authors:  Venija Cerovečki; Hrvoje Tiljak; Zlata Ožvačić Adžić; Miljenko Križmarić; Peter Pregelj; Andrej Kastelic
Journal:  Croat Med J       Date:  2013-02       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.